You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
AstraZeneca
Johnson and Johnson
Mallinckrodt
Harvard Business School

Last Updated: May 13, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BRUKINSA

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Brukinsa

Trial ID Title Status Sponsor Phase Start Date Summary
NCT04382586 Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants Not yet recruiting BeiGene Phase 2 2020-05-01 The primary objective of this study is to evaluate if the addition of zanubrutinib to supportive care increases the respiratory failure-free survival rate at Day 28 in participants hospitalized for Corona Virus Disease 2019 (COVID-19) and pulmonary distress.
NCT04470908 The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males Not yet recruiting BeiGene Phase 1 2020-07-01 The primary objective of this study is to determine the effect of the moderate cytochrome P450 3A (CYP3A) inducer rifabutin on the pharmacokinetics (PK) of zanubrutinib in healthy males.
NCT04551963 Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies Not yet recruiting BeiGene Phase 1 2020-09-18 The primary objective of this study is to assess the steady-state zanubrutinib pharmacokinetics (PK) when coadministered with moderate and strong cytochrome P450 A (CYP3A) inhibitors.
NCT04643470 Zanubrutinib in Participants With Active Proliferative Lupus Nephritis Not yet recruiting BeiGene Phase 2 2020-11-01 The primary objective of this study is to evaluate the efficacy of zanubrutinib added to standard of care as measured by complete renal response for participants with active proliferative lupus nephritis
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Brukinsa

Condition Name

Condition Name for Brukinsa
Intervention Trials
Idiopathic Multicentric Castleman's Disease 1
Healthy 1
COVID-19 Pulmonary Complications 1
COVID-19 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Brukinsa
Intervention Trials
Neoplasms 1
Infection 1
Castleman Disease 1
Lymphoma, Mantle-Cell 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Brukinsa

Trials by Country

Trials by Country for Brukinsa
Location Trials
United States 5
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Brukinsa
Location Trials
Florida 1
Wisconsin 1
New Jersey 1
Massachusetts 1
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Brukinsa

Clinical Trial Phase

Clinical Trial Phase for Brukinsa
Clinical Trial Phase Trials
Phase 3 1
Phase 2 3
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Brukinsa
Clinical Trial Phase Trials
Not yet recruiting 5
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Brukinsa

Sponsor Name

Sponsor Name for Brukinsa
Sponsor Trials
BeiGene 4
Loxo Oncology, Inc. 1
Peking Union Medical College Hospital 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Brukinsa
Sponsor Trials
Industry 5
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Dow
Merck
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.